MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-28-2026
Grifols, S.A. Total Assets 2011-2026 | GRFS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.4 B | 21 B | 21.2 B | 19.2 B | 15.3 B | 15.5 B | 12.5 B | 10.9 B | 10 K | 9.6 B | 8.45 B | 5.63 B | 2.84 B | 2.9 B |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.4 B | 10 K | 11.9 B |
Quarterly Total Assets Grifols, S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 19.2 B | - | - | - | 15.3 B | - | - | - | 15.5 B | - | - | - | 12.5 B | - | - | - | 10.9 B | - | - | - | 10.1 B | - | - | - | 9.6 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 B | 9.6 B | 13.3 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | China |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
624 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
1.08 B | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
271 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.28 B | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
490 M | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
936 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.83 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
38.9 M | $ 2.69 | -0.74 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
7.59 B | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
435 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
149 M | $ 1.23 | -2.38 % | $ 90.3 M | USA |
 |
Cabaletta Bio
CABA
|
254 M | $ 3.18 | -0.16 % | $ 3.71 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
473 M | - | -7.23 % | $ 13 M | USA |